Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy.

导出 OA

翻译打印收藏纠错

第一作者： Manhal,Izzy

第一单位： Department of Medicine, Division of Gastroenterology and Liver Diseases, Montefiore Medical Center, The Albert Einstein College of Medicine, Bronx, NY, United States.

作者： Manhal,Izzy ^[1] ; Ghalib,Jibara ^[2] ; Aws,Aljanabi ^[1] ; Mustafa,Alani ^[1] ; Emily,Giannattasio ^[1] ; Hina,Zaidi ^[1] ; Zaid,Said ^[1] ; Paul,Gaglio ^[1] ; Allan,Wolkoff ^[1] ; John F,Reinus ^[1]

作者单位： Department of Medicine, Division of Gastroenterology and Liver Diseases, Montefiore Medical Center, The Albert Einstein College of Medicine, Bronx, NY, United States. ^[1] Department of Urology, The Brookdale University Hospital and Medical Center, Brooklyn, NY, United States. ^[2]

关键词 AA, African-American APRI, aspartate-aminotransferase-to-platelet ratio index DTB, dominant treatment barrier HCC, hepatocellular carcinoma HCV, hepatitis C virus SVR, sustained virologic response hepatitis C liver fibrosis mortality progression treatment barrier

DOI 10.1016/j.jceh.2016.02.006

PMID 27493457

发布时间 2020-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交